| pubmed-article:1492597 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1492597 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1492597 | lifeskim:mentions | umls-concept:C0024117 | lld:lifeskim |
| pubmed-article:1492597 | lifeskim:mentions | umls-concept:C0085236 | lld:lifeskim |
| pubmed-article:1492597 | lifeskim:mentions | umls-concept:C0021745 | lld:lifeskim |
| pubmed-article:1492597 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:1492597 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:1492597 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1492597 | pubmed:dateCreated | 1993-3-4 | lld:pubmed |
| pubmed-article:1492597 | pubmed:abstractText | Forty-six anergic patients (37 males and 9 females, age range 55-79 yr) were selected from ninety-one patients suffering from COPD due to frequent exacerbations and impaired delayed cutaneous reactivity (43.9%). The phenotype of circulating lymphocytes, their proliferative response to a panel of polyclonal T-cell activators and the candidacidal activity (CA) of circulating PMNs (polymorphonuclear cells) were measured. In 13 patients presenting a defective CA of circulating PMNs, the in vitro response of alveolar macrophage CA to r-IFN-gamma was also determined. We found: 1) a significant reduction in the CL response to PHA in COPD patients vs controls; 2) a low PMN-CA in 23 (57%) COPD patients; 3) a non-significant difference in phenotype analysis in patients and controls; 4) lower CA of AMs in COPD patients than in controls; 5) restoration in vitro of CA by r-IFN-gamma in the group of anergic COPD patients presenting depressed CA. We conclude that a defective cell-mediated immunity could be the basis of the enhanced susceptibility to infectious exacerbations in many COPD patients and that, in vitro, it could be reversed by r-IFN-gamma treatment. | lld:pubmed |
| pubmed-article:1492597 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1492597 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1492597 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1492597 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1492597 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1492597 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1492597 | pubmed:issn | 0393-974X | lld:pubmed |
| pubmed-article:1492597 | pubmed:author | pubmed-author:ArcangeliCC | lld:pubmed |
| pubmed-article:1492597 | pubmed:author | pubmed-author:BertottoAA | lld:pubmed |
| pubmed-article:1492597 | pubmed:author | pubmed-author:VecchiarelliA... | lld:pubmed |
| pubmed-article:1492597 | pubmed:author | pubmed-author:CrupiSS | lld:pubmed |
| pubmed-article:1492597 | pubmed:author | pubmed-author:CenciEE | lld:pubmed |
| pubmed-article:1492597 | pubmed:author | pubmed-author:EslamiAA | lld:pubmed |
| pubmed-article:1492597 | pubmed:author | pubmed-author:TodiscoTT | lld:pubmed |
| pubmed-article:1492597 | pubmed:author | pubmed-author:DottoriniMM | lld:pubmed |
| pubmed-article:1492597 | pubmed:author | pubmed-author:FabiettiP GPG | lld:pubmed |
| pubmed-article:1492597 | pubmed:author | pubmed-author:MassucciMM | lld:pubmed |
| pubmed-article:1492597 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1492597 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:1492597 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1492597 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1492597 | pubmed:pagination | 87-92 | lld:pubmed |
| pubmed-article:1492597 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:meshHeading | pubmed-meshheading:1492597-... | lld:pubmed |
| pubmed-article:1492597 | pubmed:articleTitle | Interferon-gamma (r-IFN-gamma) induced activation of alveolar macrophages (AM) from anergic patients with chronic obstructive pulmonary disease (COPD). | lld:pubmed |
| pubmed-article:1492597 | pubmed:affiliation | Pulmonary Division, University Hospital of Perugia, Italy. | lld:pubmed |
| pubmed-article:1492597 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1492597 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
